Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.49 Insider Own6.55% Shs Outstand43.12M Perf Week5.04%
Market Cap263.95M Forward P/E41.18 EPS next Y0.15 Insider Trans-4.36% Shs Float40.84M Perf Month-7.79%
Income-21.28M PEG- EPS next Q-0.05 Inst Own77.60% Short Float4.45% Perf Quarter-43.02%
Sales163.73M P/S1.61 EPS this Y-5.88% Inst Trans4.16% Short Ratio5.43 Perf Half Y4.86%
Book/sh2.13 P/B2.83 EPS next Y181.48% ROA-11.32% Short Interest1.82M Perf Year-34.49%
Cash/sh0.54 P/C11.17 EPS next 5Y- ROE-22.32% 52W Range3.45 - 10.83 Perf YTD-11.57%
Dividend Est.- P/FCF- EPS past 5Y3.44% ROI-13.24% 52W High-44.24% Beta1.03
Dividend TTM- Quick Ratio2.23 Sales past 5Y13.87% Gross Margin79.73% 52W Low75.07% ATR (14)0.35
Dividend Ex-DateJan 27, 2010 Current Ratio3.43 EPS Y/Y TTM14.89% Oper. Margin-11.41% RSI (14)40.02 Volatility4.07% 6.14%
Employees428 Debt/Eq0.74 Sales Y/Y TTM13.51% Profit Margin-13.00% Recom1.00 Target Price12.67
Option/ShortYes / Yes LT Debt/Eq0.72 EPS Q/Q7.64% Payout- Rel Volume0.63 Prev Close5.97
Sales Surprise-1.38% EPS Surprise11.76% Sales Q/Q12.86% EarningsMay 02 BMO Avg Volume334.57K Price6.04
SMA20-2.76% SMA50-15.17% SMA200-12.49% Trades Volume210,247 Change1.17%
Date Action Analyst Rating Change Price Target Change
Nov-11-22Resumed Jefferies Buy $15
May-09-22Upgrade Canaccord Genuity Hold → Buy $10 → $15
Mar-11-22Resumed Cantor Fitzgerald Overweight $21
Oct-23-20Initiated Guggenheim Buy $24
Jun-16-20Resumed Cantor Fitzgerald Overweight $16
May-07-20Downgrade Canaccord Genuity Buy → Hold $12
Apr-02-20Downgrade BTIG Research Buy → Neutral
Aug-07-19Downgrade William Blair Outperform → Mkt Perform
Jul-12-19Initiated Canaccord Genuity Buy $32
Mar-02-18Reiterated Lake Street Buy $26 → $38
May-17-24 12:29PM
May-16-24 02:56PM
May-14-24 07:00AM
May-06-24 10:31AM
03:02AM Loading…
May-03-24 03:02AM
May-02-24 11:57AM
Apr-29-24 04:50PM
Apr-16-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:20AM
Mar-05-24 09:27PM
11:53AM Loading…
Feb-28-24 08:50AM
Feb-26-24 09:15AM
Feb-13-24 04:30PM
Feb-12-24 08:50AM
Feb-06-24 09:40AM
Feb-02-24 04:15PM
Jan-26-24 08:50AM
Jan-18-24 05:00PM
Jan-04-24 04:45PM
04:15PM Loading…
Dec-26-23 04:15PM
Dec-06-23 07:00AM
Dec-01-23 05:00PM
Nov-20-23 07:00AM
Nov-08-23 09:41AM
Nov-07-23 11:01PM
Nov-02-23 10:00AM
Oct-31-23 10:01AM
Oct-18-23 07:00AM
Oct-16-23 10:23AM
Sep-28-23 08:21AM
Sep-05-23 07:00AM
Aug-31-23 07:00AM
Aug-21-23 07:00AM
Aug-10-23 03:03PM
Aug-08-23 10:59AM
Aug-07-23 05:25PM
Aug-03-23 05:55PM
Jul-27-23 07:00AM
Jul-26-23 07:00AM
Jun-10-23 10:42AM
Jun-09-23 09:55AM
May-24-23 07:00AM
May-12-23 07:00AM
May-09-23 08:35AM
Apr-18-23 04:05PM
Mar-17-23 04:31AM
Mar-16-23 06:30AM
Mar-14-23 11:23PM
Mar-06-23 07:00AM
Mar-02-23 04:00PM
Mar-01-23 09:21AM
Feb-13-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Jan-01-23 08:52AM
Dec-19-22 07:00AM
Nov-11-22 08:50AM
Nov-08-22 08:15AM
Nov-03-22 04:00PM
Oct-31-22 07:00AM
Oct-27-22 12:00PM
Oct-20-22 07:00AM
Oct-19-22 09:40AM
Sep-29-22 05:32AM
Sep-22-22 09:55AM
Aug-08-22 09:55AM
Aug-03-22 05:25PM
Jul-29-22 07:00AM
Jul-25-22 08:24AM
Jul-20-22 03:26PM
Jul-18-22 04:00PM
Jul-11-22 07:00AM
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scopelianos AngeloChief R&D OfficerMar 21 '24Option Exercise0.002,500058,604Mar 25 09:37 PM
Zaderej Karen L.CEOMar 21 '24Sale7.6839,280301,6701,124,565Mar 25 09:43 PM
Scopelianos AngeloChief R&D OfficerMar 21 '24Sale7.686,88152,84652,999Mar 25 09:37 PM
Donovan Michael PatrickVP OperationsMar 21 '24Sale7.686,03346,33337,992Mar 25 09:22 PM
DeVinney Erick WayneChief Innovation OfficerMar 21 '24Sale7.684,57835,159165,661Mar 25 09:40 PM
Zaderej Karen L.CEOMar 16 '24Option Exercise0.00110,32201,157,593Mar 25 09:43 PM
DeVinney Erick WayneChief Innovation OfficerMar 16 '24Option Exercise0.0018,6750180,615Mar 25 09:40 PM
Scopelianos AngeloChief R&D OfficerMar 16 '24Option Exercise0.0025,406058,250Mar 25 09:37 PM
Donovan Michael PatrickVP OperationsMar 16 '24Option Exercise0.0024,575058,846Mar 25 09:22 PM
Donovan Michael PatrickVP OperationsMar 07 '24Sale8.8136,310319,89135,708Mar 08 05:33 PM
Freitag Gregory GeneDirectorMar 07 '24Sale9.0025,000225,000271,594Mar 08 05:31 PM
MARIANI PETER JEVP & Chief Financial OfficerDec 11 '23Sale7.5012,50093,80963,603Dec 13 04:07 PM
Wendell Amy McBrideDirectorSep 06 '23Buy6.2210,00062,24080,342Sep 08 04:20 PM
Burke William P. Mr.DirectorAug 23 '23Buy6.5610,00065,60010,000Aug 25 04:16 PM
NEELS GUIDO JDirectorAug 16 '23Buy6.1110,00061,10068,259Aug 18 04:12 PM
Freitag Gregory GeneDirectorJun 01 '23Option Exercise0.006,4590296,594Jun 05 06:47 PM
NEELS GUIDO JDirectorJun 01 '23Option Exercise0.006,459058,259Jun 05 06:52 PM
JOHNSON JOHNDirectorJun 01 '23Option Exercise0.006,45906,459Jun 05 06:53 PM
Levine Alan MDirectorJun 01 '23Option Exercise0.006,459018,259Jun 05 06:57 PM
THOMAS PAULDirectorJun 01 '23Option Exercise0.006,45909,495Jun 05 06:22 PM
Wendell Amy McBrideDirectorJun 01 '23Option Exercise0.006,459070,342Jun 05 06:24 PM
Freitag Gregory GeneDirectorJun 01 '23Sale8.7141,980365,780290,135Jun 05 06:47 PM
Freitag Gregory GeneDirectorMay 23 '23Sale9.237,46868,899332,115May 24 04:12 PM